Monica Bellei

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1363509/publications.pdf

Version: 2024-02-01

53 papers	5,319 citations	25 h-index	197818 49 g-index
53	53	53	4535
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Follicular Lymphoma International Prognostic Index. Blood, 2004, 104, 1258-1265.	1.4	1,552
2	Follicular Lymphoma International Prognostic Index 2: A New Prognostic Index for Follicular Lymphoma Developed by the International Follicular Lymphoma Prognostic Factor Project. Journal of Clinical Oncology, 2009, 27, 4555-4562.	1.6	613
3	Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study. Blood, 2004, 103, 2474-2479.	1.4	549
4	Early Positron Emission Tomography Response–Adapted Treatment in Stage I and II Hodgkin Lymphoma: Final Results of the Randomized EORTC/LYSA/FIL H10 Trial. Journal of Clinical Oncology, 2017, 35, 1786-1794.	1.6	397
5	Omitting Radiotherapy in Early Positron Emission Tomography–Negative Stage I/II Hodgkin Lymphoma Is Associated With an Increased Risk of Early Relapse: Clinical Results of the Preplanned Interim Analysis of the Randomized EORTC/LYSA/FIL H10 Trial. Journal of Clinical Oncology, 2014, 32, 1188-1194.	1.6	349
6	Clinicopathologic Characteristics of Angioimmunoblastic T-Cell Lymphoma: Analysis of the International Peripheral T-Cell Lymphoma Project. Journal of Clinical Oncology, 2013, 31, 240-246.	1.6	287
7	Final Results of the IELSG-19 Randomized Trial of Mucosa-Associated Lymphoid Tissue Lymphoma: Improved Event-Free and Progression-Free Survival With Rituximab Plus Chlorambucil Versus Either Chlorambucil or Rituximab Monotherapy. Journal of Clinical Oncology, 2017, 35, 1905-1912.	1.6	143
8	Prognostic value of baseline metabolic tumor volume in early-stage Hodgkin lymphoma in the standard arm of the H10 trial. Blood, 2018, 131, 1456-1463.	1.4	130
9	Molecular Profiling Improves Classification and Prognostication of Nodal Peripheral T-Cell Lymphomas: Results of a Phase III Diagnostic Accuracy Study. Journal of Clinical Oncology, 2013, 31, 3019-3025.	1.6	129
10	Watchful Waiting in Low–Tumor Burden Follicular Lymphoma in the Rituximab Era: Results of an F2-Study Database. Journal of Clinical Oncology, 2012, 30, 3848-3853.	1.6	107
11	High-Dose Therapy and Autologous Stem-Cell Transplantation Versus Conventional Therapy for Patients With Advanced Hodgkin's Lymphoma Responding to Front-Line Therapy. Journal of Clinical Oncology, 2003, 21, 2320-2325.	1.6	106
12	The outcome of peripheral T-cell lymphoma patients failing first-line therapy: a report from the prospective, International T-Cell Project. Haematologica, 2018, 103, 1191-1197.	3.5	90
13	High-dose therapy and autologous stem cell transplantation versus conventional therapy for patients with advanced Hodgkin's lymphoma responding to front-line therapy: long-term results. Haematologica, 2009, 94, 146-148.	3.5	66
14	Metabolic heterogeneity on baseline 18FDG-PET/CT scan is a predictor of outcome in primary mediastinal B-cell lymphoma. Blood, 2018, 132, 179-186.	1.4	63
15	Incidence, clinical characteristics and survival of malignant lymphomas: a population-based study from a cancer registry in northern Italy. Hematological Oncology, 2007, 25, 189-197.	1.7	49
16	Peripheral T cell lymphoma, not otherwise specified (PTCLâ€NOS). A new prognostic model developed by the International T cell Project Network. British Journal of Haematology, 2018, 181, 760-769.	2.5	49
17	Long-Term Follow-Up Analysis of HD9601 Trial Comparing ABVD Versus Stanford V Versus MOPP/EBV/CAD in Patients With Newly Diagnosed Advanced-Stage Hodgkin's Lymphoma: A Study From the Intergruppo Italiano Linfomi. Journal of Clinical Oncology, 2011, 29, 4227-4233.	1.6	47
18	Incidence and outcomes of rare T cell lymphomas from the T Cell Project: hepatosplenic, enteropathy associated and peripheral gamma delta T cell lymphomas. American Journal of Hematology, 2020, 95, 151-155.	4.1	43

#	Article	IF	Citations
19	Efficacy of bendamustine and rituximab in splenic marginal zone lymphoma: results from the phase II BRISMA/IELSG36 study. British Journal of Haematology, 2018, 183, 755-765.	2.5	41
20	Concerning the mechanism of increased thermogenesis in rats treated with dehydroepiandrosterone. Journal of Bioenergetics and Biomembranes, 1993, 25, 313-321.	2.3	38
21	Prognostic relevance of serum Â2 microglobulin in patients with follicular lymphoma treated with anthracycline-containing regimens. A GISL study. Haematologica, 2007, 92, 1482-1488.	3.5	38
22	Secondary malignant neoplasms, progression-free survival and overall survival in patients treated for Hodgkin lymphoma: a systematic review and meta-analysis of randomized clinical trials. Haematologica, 2017, 102, 1748-1757.	3.5	38
23	T-Cell Lymphomas in South America and Europe. Revista Brasileira De Hematologia E Hemoterapia, 2011, 34, 42-47.	0.7	38
24	Changes in Liver Structure and Function after Short-Term and Long-Term Treatment of Rats with Dehydroepiandrosterone. Journal of Nutrition, 1992, 122, 967-976.	2.9	34
25	Reduced intensity <scp>VEPEMB</scp> regimen compared with standard <scp>ABVD</scp> in elderly Hodgkin lymphoma patients: results from a randomized trial on behalf of the Fondazione Italiana Linfomi (<scp>FIL</scp>). British Journal of Haematology, 2016, 172, 879-888.	2.5	29
26	Longâ€term overall survival and toxicities of ABVD vs BEACOPP in advanced Hodgkin lymphoma: A pooled analysis of four randomized trials. Cancer Medicine, 2020, 9, 6565-6575.	2.8	29
27	Induction of Thermogenic Enzymes by DHEA and Its Metabolites. Annals of the New York Academy of Sciences, 1995, 774, 171-179.	3.8	27
28	The Effects of the Ergosteroid 7-Oxo-dehydroepiandrosterone on Mitochondrial Membrane Potential: Possible Relationship to Thermogenesis. Archives of Biochemistry and Biophysics, 1997, 341, 122-128.	3.0	26
29	Follicular lymphoma. Revista Brasileira De Hematologia E Hemoterapia, 2011, 34, 54-59.	0.7	24
30	High response rate and improvement of long-term survival with combined treatment modalities in patients with poor-risk primary thyroid diffuse large B-cell lymphoma: an International Extranodal Lymphoma Study Group and Intergruppo Italiano Linfomi study. Leukemia and Lymphoma, 2011, 52, 823-832.	1.3	23
31	ALK-negative anaplastic large cell lymphoma: features and outcomes of 235 patients from the International T-Cell Project. Blood Advances, 2021, 5, 640-648.	5.2	22
32	Pitfalls and major issues in the histologic diagnosis of peripheral Tâ€cell lymphomas: results of the central review of 573 cases from the Tâ€Cell Project, an international, cooperative study. Hematological Oncology, 2017, 35, 630-636.	1.7	19
33	Dismal outcome of tâ€cell lymphoma patients failing firstâ€line treatment: results of a populationâ€based study from the Modena Cancer Registry. Hematological Oncology, 2015, 33, 147-151.	1.7	16
34	First Report On the H10 EORTC/GELA/IIL Randomized Intergroup Trial On Early FDG-PET Scan Guided Treatment Adaptation Versus Standard Combined Modality Treatment in Patients with Supra-Diaphragmatic Stage I/II Hodgkin's Lymphoma, for the Groupe d'Etude Des Lymphomes De l'Adulte (GELA), European Organisation for the Research and Treatment of Cancer (EORTC) Lymphoma Group and the Intergruppo Italiano Linfomi (IIL) Blood, 2009, 114, 97-97.	1.4	16
35	Prognostic factors in low-grade non-Hodgkin lymphomas. Current Hematologic Malignancy Reports, 2009, 4, 202-210.	2.3	13
36	Incidence Clinical Characteristics and Survival of Non Splenic Marginal Zone Lymphomas: A Population Based Study from a Cancer Registry in Northern Italy. Blood, 2008, 112, 3753-3753.	1.4	13

#	Article	IF	Citations
37	PET-Based Response after 2 Cycles of Brentuximab Vedotin in Combination with AVD for First-Line Treatment of Unfavorable Early-Stage Hodgkin Lymphoma: First Analysis of the Primary Endpoint of Breach, a Randomized Phase II Trial of Lysa-FIL-EORTC Intergroup. Blood, 2017, 130, 736-736.	1.4	11
38	The Value and Relevance of the T Cell Lymphoma Registries and International Collaborations: the Case of COMPLETE and the T-Cell Project. Current Hematologic Malignancy Reports, 2015, 10, 448-455.	2.3	10
39	BEACOPP or no BEACOPP?. Lancet Oncology, The, 2013, 14, e487-e488.	10.7	9
40	The outcome of peripheral T-cell lymphoma patients failing first-line therapy: a report from the prospective International T-Cell Project. Haematologica, 2019, 104, e178.2-e178.	3.5	7
41	Effect of cardiolipin on functional properties of isolated rat liver mitochondria. IUBMB Life, 1997, 41, 469-480.	3.4	6
42	Comparative studies of effects of dehydroepiandrosterone on rat and chicken liver. Comparative Biochemistry and Physiology Part B: Comparative Biochemistry, 1993, 105, 643-647.	0.2	5
43	Chlorambucil Plus Rituximab Produces Better Event-Free Survival in Comparison with Chlorambucil Alone in the Treatment of MALT Lymphoma: 5-Year Analysis of the 2-Arms Part of the IELSG-19 Randomized Study. Blood, 2010, 116, 432-432.	1.4	5
44	CD30+ expression in Peripheral T-cell lymphomas (PTCLs): A subset analysis from the international, prospective T-Cell Project Journal of Clinical Oncology, 2015, 33, 8552-8552.	1.6	4
45	Evaluation of Quality of Biomarker Data Capture by Peripheral Sites in an International, Cooperative Study: Analysis of 104 Cases From the T-Cell Project Blood, 2012, 120, 2650-2650.	1.4	3
46	T-Cell Project: an international, longitudinal, observational study of patients with aggressive peripheral T-cell lymphoma. Revista Brasileira De Hematologia E Hemoterapia, 2009, 31, .	0.7	2
47	Prognostic Value of Baseline Quantitative PET Metrics for Patients with Unfavourable Early Stage Hodgkin Lymphoma Enrolled in the Standard Arm of the EORTC/Lysa/FIL H10 Trial. Blood, 2016, 128, 184-184.	1.4	2
48	The Outcome of T-Cell Lymphoma Patients Failing First-Line Treatment: Results of a Population Based-Study From the Modena Cancer Registry. Blood, 2012, 120, 1611-1611.	1.4	1
49	The Outcome of Patients with Primary Refractory or Relapsed Peripheral T-Cell Lymphoma: Analysis of 1020 Cases Registered in the Prospective T-Cell Project. Blood, 2016, 128, 921-921.	1.4	1
50	When should a watch-and-wait strategy be adopted for follicular lymphoma?. International Journal of Hematologic Oncology, 2013, 2, 91-94.	1.6	0
51	A Predictive Model for Limited Stage Diffuse Large B-Cell Lymphoma (DLBCL): A Retrospective Analysis of 1,252 Cases Performed by the Intergruppo Italiano Linfomi (IIL) Blood, 2004, 104, 3261-3261.	1.4	0
52	Incidence, Clinical Characteristics and Survival of Malignant Lymphomas in the Province of Modena (Italy); a Population-Based Study Blood, 2006, 108, 4628-4628.	1.4	0
53	Primary Thyroid Lymphoma: A Retrospective IELSG and IIL Analysis of Clinical Characteristics, Prognostic Factors, Treatment Outcome and Somatic Hypermutation for Localized Diffuse Large B-Cell Lymphoma (DLBCL) Blood, 2007, 110, 3432-3432.	1.4	0